HER2 and response to paclitaxel in node-positive breast cancer by Hayes Daniel F, Thor Ann D, Dressler Lynn G, Weaver Donald, Edgerton Susan, Cowan David, Broadwater Gloria, Goldstein Lori J, Martino Silvana, Ingle James N, Henderson I Craig, Norton Larry, Winer Eric P, Hudis Clifford A, Ellis Matthew J, Berry Donald A, Cancer and Leukemia Group B (CALGB) Investigators in The New England journal of medicine (2007).

[PMID: 17928597] PubMed


The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.